18
Dec

2014

Independent support for the role of microglia in Alzheimer’s disease

I was very excited to read about research recently published by a group from Stanford regarding the potential role for microglia in Alzheimer’s disease (http://med.stanford.edu/news/all-news/2014/12/blocking-receptor-in-brains-immune-cells-counters-alzheimers.html). While the work by Karin Andreasson and her team focuses on a receptor protein called EP2, the underlying conclusions of her research – that restoring the activity of microglia to…more »

18
Nov

2014

GliaCure’s Lead Product, GC021109, Receives FDA Fast Track Designation

GliaCure’s lead product candidate for Alzheimer’s disease, GC021109, has been awarded Fast Track status by the FDA. Biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. The Fast Track…more »

25
Sep

2014

GliaCure Enters First-in-Human Clinical Trial in Alzheimer’s Disease

GliaCure today distributed the following press release: GliaCure, a privately-held biotechnology company focused on the development of novel therapies for neurological and neuropsychiatric disorders based on glial targets, announced today that has initiated dosing of healthy volunteers in a first-in-human Phase 1a clinical trial of its lead product candidate, GC021109, a novel compound developed as…more »

21
Aug

2014

New 3-D model of Brain Tissue Mimics Brain Function

GliaCure President Phil Haydon was co-author of a paper published in the Proceedings of the National Academy of Sciences (Tang-Schomer et al, 2014) and featured recently in the New York Times (August 11, 2014). This paper described the creation and potential uses of synthetic 3-D brain-like tissue. This tissue, composed of a modular design of…more »

16
Aug

2014

GliaCure Closes on $5.8 Million Financing

B round financing with new and existing investors will advance GliaCure’s Alzheimer’s clinical program  GliaCure, Inc., a company focused on developing novel, non-neuronal therapies for a range of neurological and neuropsychiatric disorders, today announced that it has successfully completed a $5.8 million B round financing, exceeding its original goal of $5 million. This financing round…more »

16
Aug

2014

GliaCure Appoints New Member to Board of Directors

Mr. Zakrzewski is a Seasoned Life Sciences Leader  GliaCure, Inc., a company focused on developing novel, non-neuronal therapies for a range of neurological and neuropsychiatric disorders, announced today that it has appointed Joseph S. Zakrzewski to the Company’s Board of Directors.  Mr. Zakrewski brings more than 20 years of experience to his new role as…more »

16
Jun

2014

Rudy Schreiber – New VP of Translational Research and Development

GliaCure is pleased to announce that Dr. Rudy Schreiber has joined the team as Vice President of Translational Research and Development. Dr. Schreiber previously held positions at Roche, Sepracor and Evotec, where he developed expertise and leadership in behavioral studies with a specific focus on CNS projects. His experience as a scientist and as a…more »

06
Mar

2014

Alzheimer’s deaths significantly under-reported

A recent study out of Rush University Medical Center in Chicago and published in the journal Neurology reports that deaths due to Alzheimer’s disease are greatly under-reported. The death certificate and  medical records of Alzheimer’s patients frequently list the immediate cause of death, such as pneumonia, rather than the underlying cause, which is the inability to fight…more »

26
Feb

2014

Glia and ALS

On February 10, 2014 the ALZFORUM (www.alzforum.org) highlighted work by a team from Columbia University showing that astrocytes, a specialized type of glia cell, cause the death of motor neurons in an in vitro study of cells from ALS patients. The authors of the study are now trying to identify the toxic factor that astrocytes…more »

26
Feb

2014

The role of gliotransmitters

GliaCure President Phil Haydon recently co-authored a review in the journal Neuron on gliotransmitters and the interplay between glia and neuron in signaling in the brain.

Page 2 of 5